Comments (1)
![ACT-001 got FDA Orphan Drug Designation](/modules//smartblog/images/8-home-default.jpg)
Glioblastoma multiforme (GBM) new medicine ACT-001 got FDA Orphan drug designation on 8th Nov, but still need to wait approved for orphan indication. In the phase I clinical trials in Australia, the result is better than TEMODAR(Temozolomide). The new medicine is applied by Accendatech USA Incorporated and also for Acute Myeloid Leukemia.
BonHoa Pharmacy will pay constant attention on the development of ACT-001. For more Glioblastoma Multiforme (GBM) medicine please visit us.
David M Nov 25, 2017
Hope it comes to market ASAP